CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancerGerard Walls, Alastair Greystoke, Crispin T. Hiley et al.|Clinical and Translational Radiation Oncology|2020Cited by 34
The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid CancerJ. Taprogge, Glenn Flux, Carla Abreu et al.|Journal of Nuclear Medicine|2023Cited by 19
Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine TrialMartin Kaiser, Matthew Jenner, Rachel Phillip et al.|Blood|2023Cited by 8
Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDEKatrina Walker, Samantha Hinsley, Rachel Phillip et al.|JCO Precision Oncology|2022Cited by 4
CTIM-14. PELAREOREP AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) WITH STANDARD CHEMORADIOTHERAPY/ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS: REOGLIO PHASE I TRIAL RESULTSJessica Kendall, Susan Short, Anthony J. Chalmers et al.|Neuro-Oncology|2020Cited by 3